SomaSignal Test for MASH/NASH
Metabolic Dysfunction-Associated Steatohepatitis
DevelopmentActive
Key Facts
Indication
Metabolic Dysfunction-Associated Steatohepatitis
Phase
Development
Status
Active
Company
About SomaLogic
Founded in 2000, SomaLogic's mission is to decode the human proteome to revolutionize life sciences and healthcare. Its core achievement is the SomaScan Platform, which leverages proprietary SOMAmer® reagents and KREX™ technology to deliver unparalleled scale, sensitivity, and reproducibility in protein measurement. The company's strategy focuses on providing fee-for-service assay services globally, expanding its menu of SomaSignal diagnostic tests, and leveraging its 2024 merger with Standard BioTools to accelerate leadership in integrated multi-omics solutions.
View full company profileTherapeutic Areas
Other Metabolic Dysfunction-Associated Steatohepatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| MASH/Liver Health Screening | IMA Clinical Research | Not Applicable (Service) |
| AIM-MASH | PathAI | FDA Qualified for Trials |